Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC Vaccine in Stage IV Melanoma
NCT00126685Phase 2Unknown
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Apr 2005
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous tumor RNA-transfected dendritic cells in cutaneous melanoma (CM) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoints: Safety and tolerability, Tumor RNA- or tumor antigen-specific T-cell responses and 4 more. Status: unknown.
02
Drugs
autologous tumor RNA-transfected dendritic cells
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT00126685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126685.